An HPLC technique was devised and validated for the concurrent analysis of Cefpodoxime Proxetil and Levofloxacin in tablet dosage form. The drugs were separated using chromatography on a Hypersil BDS C8 column (250 mm x 4.6 mm, 5 μ) as the stationary phase. The mobile phase consisted of a mixture of phosphate buffer (pH adjusted to 4.5 with orthophosphoric acid), methanol, and acetonitrile in a ratio of 55:25:20 (v/v/v). The separation was performed at a flow rate of 1.0 mL/min, and the detection of the drugs was carried out using UV detection at a wavelength of 222 nm. The retention time for Cefpodoxime Proxetil was seen to be 4.07 minutes, while for Levofloxacin it was 6.13 minutes. The methodology employed in this study was determined to be highly selective, as evidenced by the clear separation of the peaks corresponding to Cefpodoxime Proxetil and Levofloxacin. The resolution achieved between these peaks was measured to be 9.82. The approach suggested in this study demonstrates linearity, as seen by the high coefficient of determination (R2 = 0.999) obtained for both Cefpodoxime Proxetil and Levofloxacin. Furthermore, the method exhibits accuracy, with recovery rates ranging from 99.45% to 100.08% for Cefpodoxime Proxetil and Levofloxacin. Additionally, the method demonstrates precision, as indicated by the low relative standard deviation (%RSD < 2%). The aforementioned methodology has been employed to ascertain the efficacy of the commercial product, resulting in the determination that its potency falls within the acceptable range. The present methodology is applicable for the quantitative analysis of Cefpodoxime Proxetil and Levofloxacin in tablet formulations.